{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.4","upperLimit":"48.4","value":"6.3"},{"groupId":"OG001","lowerLimit":"5","upperLimit":"37.1","value":"12.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"description":"Time from date of randomization to first documentation of objective tumor response. TTR was calculated for the subgroup of participants with objective tumor response. Objective tumor response was defined as CR or PR according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\\<10 mm short axis). PR: at least 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.","dispersionType":"Full Range","groups":[{"description":"Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"OG000","title":"Crizotinib"},{"description":"Pemetrexed 500 mg/m\\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"FAS included all participants who were randomized to study treatment. Here 'N' (number of participant analyzed) signifies participants with objective tumor response.","reportingStatus":"POSTED","timeFrame":"Randomization until PD or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks)","title":"Time to Tumor Response (TTR)","type":"SECONDARY","unitOfMeasure":"weeks"}